BMO Upgrades Halozyme to Outperform; BSD Announces Sale of the MicroThermX® in Turkey Print E-mail
By Staff and Wire Reports   
Monday, 14 January 2013 20:21
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 14, 2013.

BMO Capital upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Outperform with a price target of $12.00 (from $4.00).  Shares of Halozyme Therapeutics closed at $7.21 yesterday, with a 52 week range of $3.86-$13.50.


BSD Medical Corporation (NASDAQ:BSDM)
, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has sold multiple MicroThermX® Microwave Ablation (MicroThermX®) systems and antennas to ADA Medikal (ADA), pursuant to their exclusive distribution agreement signed in October 2012 for the MicroThermX® in Turkey. ADA is a leading, medical, specialty distributor in Turkey with offices in the major metropolitan areas. ADA represents a number of major medical device companies and sells strategically adjacent products to the same clinicians targeted for the MicroThermX®.

Turkey is an important international market with a population of more than 73 million and the world's 15th largest economy. ADA projects that they will need to order a significant number of systems to address the market for the MicroThermX® in Turkey. Turkey's location at the crossroads of Europe and Asia and its growing economy have led to its recognition as a regional power in the Middle East.

Also Monday:

22nd Century Group, Inc. (OTCQB/OTCBB: XXII)
announced today that it closed a private placement on Friday, January 11, 2013 with an institutional investor.

Abbott (NYSE: ABT)
will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Accelrys, Inc. (NASDAQ: ACCL)
, a leading provider of scientific innovation lifecycle management software, is solidifying its market leadership in the laboratory informatics space with the acquisition of its long-time partner Vialis AG, a leading systems integrator based in Liestal, Switzerland serving the pharmaceutical, biotechnology, chemicals, and agro-science industries.

ALR Technologies Inc. (OTCBB: ALRT)
has begun the commercial launch of the Health-e-Connect System for diabetes care in the United States and is releasing a detailed marketing video.

AmbiCom Holdings, Inc. (OTCQB: ABHI)
, a leading designer and developer of wireless products for the medical and automotive industries, and a distributor of innovative healthcare products, today announced that they have signed a memorandum of understanding (MOU) with Taiwan-based Alamo Technology Service Co., Ltd., a private company.

BioRestorative Therapies, Inc. (OTCBB: BRTX)
, a life sciences company focused on adult stem cell (non-embryonic) based cellular therapies for various personal medical applications, announced today that it has been invited to present at the Adipose Tissue Biology conference of the Keystone Symposia conference series on January 30, 2013.

a leader in telemedicine services for patient diagnosis and management -- announced a change in management.

Connectyx Technologies Holdings Group, Inc. (PINKSHEETS: CTYX),, a Healthcare Business Process Outsourcing (BPO) company with wholly-owned subsidiary companies in Personal Emergency Response Systems (PERS) and other personal health product offerings, announced today that the company has entered into a binding letter of intent with Essential Strategic Partners Group (ESP Group) of Tinton Falls, New Jersey, to launch a national marketing campaign incorporating television infomercials for its Medical Alert US subsidiary, GuardianOne™ Personal Emergency Response System.

Covidien (NYSE:COV)
, a leading global provider of healthcare products, today announced the launch of a new study, SWIFT PRIME, which enrolled its first patient at the University at Buffalo.

Cytomedix, Inc. (OTCQX: CMXI)
(the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that it has received the 2012 North American Frost & Sullivan New Product Innovation Award for its Angel® concentrated platelet-rich plasma (cPRP) system.

Cytomedix, Inc. (OTCQX: CMXI)
(the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies announced today that Martin Rosendale, chief executive officer, will present at "NINE," Noble Financial Capital Markets' Ninth Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida, on Wednesday, January 23rd at 11.00 am EST.

InterMune, Inc. (Nasdaq: ITMN)
today announced that it plans to offer, subject to market and other conditions, $85.0 million aggregate principal amount of convertible senior notes due 2017 and 12,500,000 shares of its common stock in concurrent underwritten public offerings.  

Medidata Solutions (NASDAQ: MDSO)
, a leading global provider of cloud-based clinical development solutions, today announced that Bryan Spielman, executive vice president of strategy and corporate development, and Cory Douglas, chief financial officer, will present at the 2013 Needham Growth Conference on January 15, 2013 at 12:45 p.m. EST in New York City.

NanoViricides, Inc. (OTC BB: NNVC)
(the "Company") announced today that it has retained AES Clean Technology, Inc. (“AES”), for the design, engineering, and construction of the Cleanroom Suite for its laboratory and cGMP pilot production facility project.

Pfizer Inc. (NYSE: PFE)
today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).

PharMerica Corporation (NYSE: PMC)
, a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that it has appointed Patrick G. LePore to the Company’s Board of Directors.

Proteonomix, Inc. (PINK:PROT)
, a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has extended the record date for shareholders on that date to receive shares of the new BVI (British Virgin Islands) corporation that will receive sublicenses and assignments of the UMK-121 and Proteoderm technologies.

PURE Bioscience, Inc. (NASDAQ: PURE)
, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, is advising its institutional and household customers of the effectiveness of PURE™ Hard Surface disinfectant in killing various flu viruses, and emphasizing the product’s 24-hour residual protection capability.

Revolutions Medical Corporation (OTCQB: RMCP)
signs branded distribution agreement with Cardinal Health, Inc. for the RevVac™ auto-retractable vacuum safety syringe.

Rockwell Medical (NASDAQ: RMTI)
, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that Professor Francesco Locatelli, MD, FRCPB has joined the Company's Scientific Advisory Board (SAB). Rockwell's SAB consists of some of the leading anemia experts worldwide in the renal space and advises the Company on clinical and commercial development of SFP, its late-stage investigational iron-delivery drug currently in Phase 3 clinical study.

University General Health System, Inc. (OTCQB: UGHS)
, a diversified, integrated multi-specialty health care delivery system, today announced that it will be presenting at the Noble Financial Capital Markets 9thAnnual Equity Conference.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus